Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
NEW YORK, Dec. 23, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc (NYSE:AGN) and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive (the “Class Period”) of the important January 3, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks recovery of investor losses. Investors with losses in excess of $1 million are encouraged to contact the firm about the lead plaintiff deadline.
To join the Allergan class action, go to http://www.rosenlegal.com/cases-980.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Allergan and Actavis were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion; (3) in turn, Allergan and Actavis lacked effective internal controls; and (4) as a result, Allergan plc’s and Actavis plc’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-980.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
